← Back to All Filings

Natera Co-Founder Sells $3.2M in Shares Under 10b5-1 Plan

Low SignificanceSeptember 18, 2026 at 1:37:40 AM UTC

Natera, Inc.

$NTRA4CIK: 0001604821

Subscribe to track NTRA

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Natera Co-Founder Sells $3.2M in Shares Under 10b5-1 Plan

Company: Natera, Inc. (NTRA) Form: 4 | Filed: 2026/09/18 Significance: Low

Insider: Jonathan Sheena Title: Co-Founder | Relationship: Director

Transaction: • Type: Sell • Shares: 9,150 • Price: $351.49 (weighted average) • Value: $3,216,145 • Owned After: 221,314

Key Insight: Routine automated diversification under a pre-established Rule 10b5-1 trading plan adopted in December 2025, representing less than 4% of the insider's direct equity position.

Market Context: The transaction accounts for ~0.0065% of Natera's $49.27B market capitalization, presenting negligible dilution or liquidity impact on the broader market.

Comprehensive Analysis

SEC Filing Analysis: Natera, Inc. (NTRA)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: Co-Founder and Director Jonathan Sheena liquidated 9,150 shares for ~$3.22M via a scheduled Rule 10b5-1 trading plan.
  • Market Impact: Neutral; immaterial transaction volume relative to Natera's large-cap valuation.

Company Information

FieldValue
CompanyNatera, Inc.
Ticker SymbolNTRA
CIK0001604821
IndustryMedical Laboratories

Insider Information

FieldValue
NameSheena Jonathan
CIK0001646649
Title/PositionCo-Founder
RelationshipDirector

Transaction Details

FieldValue
Form Type4
Transaction Date2026-09-15
Transaction CodeS (Open market sale)
Security TypeCommon Stock
Shares Involved9,150
Price Per Share$351.49
Total Value$3,216,145
Shares Owned After221,314
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$3,216,145
% of Market Cap0.0065%
Shares Transacted9,150
% of Shares Outstanding0.0064%
Post-Transaction Ownership221,314 shares (0.15% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a large-cap company valued at $49.27B, a $3.22M sale is routine and well below the 0.1% threshold for material trading interest.
  • Ownership Concentration: The insider maintains a direct holding of 221,314 shares (0.15% of outstanding), alongside 36,064 indirect shares held across Caraluna trusts.
  • Transaction Significance: The sale represented only ~3.97% of the insider's direct holdings prior to the transactions, executed entirely under a pre-scheduled Rule 10b5-1 plan established on December 12, 2025.

Market Impact Analysis

  • Direction: Neutral
  • Reasoning: Pre-planned programmatic selling under Rule 10b5-1 with minimal market capitalization footprint.
  • Expected Volume Impact: Negligible relative to typical NTRA daily trading liquidity.
  • Sentiment Indicator: Neutral

Additional Context

  • Special Circumstances: Executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025 across multiple weighted-average tranches ranging from $348.03 to $357.06.
Topics:#SECFiling#NTRA#Natera#Form4#InsiderSell#Biotech#StockMarket

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.